Clearmind Medicine (CMND) News Today → Charles Payne Demystifies Options (From Unstoppable Prosperity) (Ad) Free CMND Stock Alerts $1.29 +0.01 (+0.78%) (As of 05/16/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 10, 2024 | globenewswire.comClearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage ProductMay 7, 2024 | msn.comWhy Clearmind Medicine Stock Is Moving HigherMay 7, 2024 | finanznachrichten.deClearmind Medicine Inc.: Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD TreatmentMay 7, 2024 | globenewswire.comClearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD TreatmentMay 1, 2024 | finanznachrichten.deClearmind Medicine Inc.: Clearmind Applies to Cease Being a Reporting Issuer in CanadaApril 30, 2024 | globenewswire.comClearmind Applies to Cease Being a Reporting Issuer in CanadaApril 17, 2024 | msn.comClearmind signs agreement for psychedelic compounds for mental disorders treatmentApril 17, 2024 | finance.yahoo.comClearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental DisordersApril 17, 2024 | globenewswire.comClearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental DisordersApril 11, 2024 | uk.investing.comClearmind Medicine advances trial for alcohol use disorder treatmentApril 10, 2024 | finanznachrichten.deClearmind Medicine Inc.: Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating DisordersApril 10, 2024 | globenewswire.comClearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating DisordersApril 9, 2024 | finanznachrichten.deClearmind Medicine Inc.: Clearmind Medicine CEO Issues Letter to ShareholdersApril 9, 2024 | globenewswire.comClearmind Medicine CEO Issues Letter to ShareholdersMarch 29, 2024 | uk.investing.comClearmind Medicine files tenth patent for depression treatmentMarch 27, 2024 | finanznachrichten.deSciSparc Ltd: SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating DepressionMarch 27, 2024 | finanznachrichten.deClearmind Medicine Inc.: Clearmind Medicine Announces International Patent Application for Preventing and Treating DepressionMarch 27, 2024 | globenewswire.comClearmind Medicine Announces International Patent Application for Preventing and Treating DepressionMarch 19, 2024 | globenewswire.comBreakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in ChinaMarch 13, 2024 | finanznachrichten.deClearmind Medicine Inc.: Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities ExchangeMarch 13, 2024 | finanznachrichten.deClearmind Medicine Inc.: Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical TrialMarch 13, 2024 | msn.comClearmind Medicine receives nod for delisting of shares from Canadian Securities ExchangeMarch 13, 2024 | globenewswire.comClearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical TrialMarch 13, 2024 | globenewswire.comClearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities ExchangeMarch 12, 2024 | msn.comPodcast: Clearmind's Non-Hallucinogenic Psychoactive Molecule Could Become A Solution For Addictive BehaviorsFebruary 27, 2024 | msn.comEXCLUSIVE: Psychedelic-Focused Firm Clearmind Medicine Submits Three New International Patent Applications For MDMA, Ibogaine And Ketamine CompoundsFebruary 27, 2024 | globenewswire.comClearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine CompoundsFebruary 23, 2024 | globenewswire.comClearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use DisorderFebruary 22, 2024 | benzinga.comClearmind Medicine Stock (NASDAQ:CMND), Quotes and News SummaryFebruary 21, 2024 | benzinga.comNext-Gen Psychedelics Companies SciSparc And Clearmind Collaboration File 3 PatentsFebruary 20, 2024 | msn.comWhat's Going On With Psychedelic Drug-Developers SciSparc And Clearmind Stock?February 20, 2024 | finance.yahoo.comClearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based CompoundsFebruary 20, 2024 | finance.yahoo.comSciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based CompoundsFebruary 20, 2024 | globenewswire.comClearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based CompoundsFebruary 14, 2024 | proactiveinvestors.comClearmind Medicine receives Patent Approval in China for treatment of binge behavioursFebruary 10, 2024 | ca.finance.yahoo.comClearmind Medicine Inc (CWY0.MU)February 5, 2024 | finanznachrichten.deClearmind Medicine Inc.: Clearmind Medicine Receives Patent Approval for its Psychedelic Based Treatment of Binge Behaviors in ChinaFebruary 5, 2024 | finance.yahoo.comClearmind Medicine Receives Patent Approval for its Psychedelic Based Treatment of Binge Behaviors in ChinaFebruary 1, 2024 | msn.comClearmind stock rallies on cocaine addiction treatment updateFebruary 1, 2024 | finance.yahoo.comClearmind Medicine Announces Exclusive, Long-Term Licensing Agreement with Leading Israeli Research CenterJanuary 16, 2024 | finanznachrichten.deAegis Capital Corp. Acted as Sole Bookrunner on a $2.4 Million Registered Direct and Private Placement for Clearmind Medicine Inc.January 16, 2024 | finance.yahoo.comClearmind Medicine Inc. Closes US$2.4 Million Registered Direct and Private PlacementJanuary 16, 2024 | finance.yahoo.comAegis Capital Corp. Acted as Sole Bookrunner on a $2.4 Million Registered Direct and Private Placement for Clearmind Medicine Inc. (NASDAQ: CMND)January 11, 2024 | marketwatch.comClearmind Medicine Shares Drop 45% After Pricing of Direct OfferingJanuary 11, 2024 | msn.comWhy Clearmind Medicine (CMND) Shares Are NosedivingJanuary 11, 2024 | msn.comClearmind Medicine looks to raise $2.4 million through private placementJanuary 11, 2024 | investorplace.comWhy Is Clearmind Medicine (CMND) Stock Down 24% Today?January 10, 2024 | finanznachrichten.deClearmind Medicine Inc.: Clearmind Medicine Completed Type A Meeting with the FDAJanuary 10, 2024 | marketwatch.comClearmind Medicine Shares Rise 51% After Type A FDA MeetingJanuary 10, 2024 | markets.businessinsider.comClearmind Medicine Says It Completed Type A Meeting With FDA; Stock Up 38% Get Clearmind Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for CMND and its competitors with MarketBeat's FREE daily newsletter. Email Address Biden FINISHED On June 13th? (Ad)Thanks to Biden’s disgraceful leadership we now have sky-high inflation… unchecked immigration… rampant crime… and a “woke mob” hell bent on destroying the America you and I know and love. Biden’s days are numbered. Click here now to see his shocking evidence. CMND Media Mentions By Week CMND Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CMND News Sentiment▼1.250.55▲Average Medical News Sentiment CMND News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CMND Articles This Week▼22▲CMND Articles Average Week Get Clearmind Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for CMND and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: BPTH News Today GLMD News Today PXMD News Today QLGN News Today DRMA News Today ALLR News Today PRFX News Today ATNF News Today SLRX News Today CNSP News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CMND) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersCharles Payne Demystifies OptionsUnstoppable ProsperityGold Set to EXPLODE!Gold Safe ExchangeBiden FINISHED On June 13th?Paradigm PressThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingHow Biden has already won 2024Porter & CompanyWhy Is Gold On a MASSIVE rally? Huge AlertsProtect Your Bank Account Before It’s Too LateWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clearmind Medicine Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
